Donor-specific HLA antibody (DSA)-mediated graft injury is the major cause of kidney loss. Among DSA characteristics, graft homing has been suggested as an indicator of severe tissue damage. We analyzed the role of de novo DSA (dnDSA) graft homing on kidney transplantation outcome. Graft biopsy specimens and parallel sera from 48 nonsensitized pediatric kidney recipients were analyzed. Serum samples and eluates from graft biopsy specimens were tested for the presence of dnDSAs with flow bead technology. Intragraft dnDSAs (gDSAs) were never detected in the absence of serum dnDSAs (sDSAs), whereas in the presence of sDSAs, gDSAs were demonstrated in 72% of biopsy specimens. A significantly higher homing capability was expressed by class II sDSAs endowed with high mean fluorescence intensity and C3d-and/or C1q-fixing properties. In patients with available sequential biopsy specimens, we detected gDSAs before the appearance of antibody-mediated rejection. In sDSApositive patients, gDSA positivity did not allow stratification for antibody-mediated graft lesions and graft loss. However, a consistent detection of skewed unique DSA specificities was observed over time within the graft, likely responsible for the damage. Our results indicate that gDSAs could represent an instrumental tool to identify, among sDSAs, clinically relevant antibody specificities requiring monitoring and possibly guiding patient management.
Introduction
In recent years, routine use of highly sensitive alloantibody detection assays clarified the role of HLA antibodies as the central cause leading to tissue damage and failure of kidney transplants (1) (2) (3) (4) (5) (6) (7) (8) (9) . In particular, bead-based Luminex technology underscored the negative impact of circulating de novo donor-specific HLA antibodies (dn sDSAs) on graft outcome also in populations of nonimmunized patients, traditionally considered at low risk for graft loss (6, (11) (12) (13) .
However, the real graft-damaging potential of dn sDSAs is not yet completely clarified, as a proportion of patients developing dn sDSAs do not show relevant graft damage even at long-term follow-up (8, 14) . Complement-binding capability, detected as C1q-fixing property and, more recently, as C3d-binding activity, has been indicated in solid organ transplant recipient as one of the intrinsic antibody properties reflecting damaging potential (15, 16) . Further, recent data obtained in adult kidney graft recipients indicated that DSA graft homing should be considered as a promising biomarker for antibody-mediated graft lesions and worse graft outcome (17) . Taken together, these studies, conducted in cohorts including a proportion of pretransplantation sensitized patients, suggest that intrinsic antibody properties have a stronger prognostic impact than the mere serum DSA presence.
In this regard, analysis of nonsensitized allograft recipients may contribute further insight into the antibodymediated stepwise process leading to graft damage, as the appearance of dn sDSAs represents a first set response in a na€ ıve individual, and any prospective observation recapitulates the natural history of alloresponses eventually leading to antibody-mediated rejection (AMR) and graft loss. In a pediatric cohort of pretransplantation HLA antibody-negative recipients of a first kidney graft followed long term, we carried out a parallel analysis on sDSAs and intragraft DSAs (gDSAs), with the aim of identifying early biomarkers for risk stratification. In detail, we evaluated (i) the impact of DSA graft homing on tissue damage and graft outcome and (ii) the role played by HLA antibody strength and complement binding ability on dn sDSA graft homing.
Patients and Methods

Patients
This retrospective study includes 48 pediatric recipients who underwent kidney transplant biopsy between March 2002 and March 2013 at the Genoa Pediatric Kidney Transplant Center and had frozen biopsy tissue remnants quantitatively suitable for study purposes.
All patients received a first allograft and tested negative before transplantation for the presence of HLA antibodies as measured by both complement-dependent cytotoxicity panel reactive assay and bead-based Luminex technology. Biopsies were performed "for cause," represented by an unexplained increase in serum creatinine, proteinuria, or detection of dn sDSAs. The availability of blood samples drawn on the same day of the biopsies represented a mandatory inclusion criterion. After transplantation, monitoring of de novo HLA antibody development was carried out using patient sera collected every 3 months in the first posttransplantation year, twice in the second posttransplantation year, and annually thereafter until the last follow-up.
Our standard of care for this cohort of low-immunological risk patients consisted of induction with basiliximab and a triple-drug immunosuppressive regimen of a calcineurin inhibitor, mycophenolate mofetil, and prednisone. Biopsy-proven acute cellular rejection episodes were treated with pulse intravenous methylprednisolone. Patients developing late AMR, as evidenced by circulating HLA DSAs and histological features of antibody-mediated tissue and vascular injuries, were treated with a protocol that included a combination of plasmaphereses, intravenous human immunoglobulin, and anti-CD20 monoclonal antibody. Patients exhibiting sDSAs, in the absence of histological signs of AMR, did not receive any additional treatment beyond standard immunosuppression.
Follow-up ranged between 2.3 and 13.8 years, with a median of 7.6 years. Demographics and clinical details of the cohort are shown in Table 1 . Graft function was estimated by calculating estimated glomerular filtration rate (eGFR) using the Schwartz (18) 
Graft biopsies
Tissue remnants of the nonfixed, frozen biopsy core that had been used for immunofluorescence analysis were included in this study. To limit the potential occurrence of negative results, due to material paucity, only fragments weighting at least 1 mg were used for the analysis of gDSAs.
A total of 65 biopsy specimens from the 48 patients were suitable for this study (Figure 1) . Thirty-four patients underwent one biopsy, 11 patients underwent two biopsies, and 3 patients underwent three biopsies. Biopsies were histologically graded following Banff 97 criteria with Banff 2013 updates (20, 21) . C4d staining was performed on frozen sections via indirect immunofluorescence. Graft biopsies were categorized into five groups: group 1: nonrejection (e.g. calcineurin inhibitor toxicity, glomerulonephritis, interstitial fibrosis, tubular atrophy, or acute tubular necrosis); group 2: borderline changes (T cell-mediated rejection [TCMR]); group 3: TCMR; group 4: microvascular inflammation (MI; e.g. presence of peritubular capillaritis or glomerulitis not reaching the Banff score to be classified as AMR; and group 5: AMR.
HLA antibody elution from kidney graft biopsies
Remnant fragments of frozen kidney graft biopsy specimens were thawed at room temperature and processed for antibody acid elution as described (17) . Briefly, cell pellets obtained after biopsy mincing were washed four times with 1.5 mL of phosphate-buffered saline (pH 7.2), to remove any recipient blood and extracellular fluid contamination. Cell pellets were resuspended in 0.1 mL of acid elution buffer (glycine solution at pH 2.1), incubated for 10 min at room temperature, and centrifuged at 6000 rpm for 2 min. The eluates were recovered and neutralized to pH 6.5 using 0.1 mL of buffering solution (Tris[hydroxymethyl]aminomethane solution at pH 8.5) and stored at À80°C until antibody analysis.
HLA typing and detection and characterization of HLA antibodies
HLA class I and class II typing, including DQA1 and DQB1 loci, was performed as previously described (22) .
Anti-HLA class I and class II IgG antibodies were tested with a beadbased detection assay. We used both the LABScreen Mixed kit (One Lambda Inc., Canoga Park, CA), which simultaneously detects class I and class II antibodies, and the single-antigen bead (SAB) assays (Single Antigen kit, One Lambda) to identify HLA class I and class II specificities in all samples. The tests were carried out according to the manufacturer's instructions, and the analysis was performed with One Lambda software (HLA Visual Version 2.2) (22) .
For sera analysis, screening assay results above a cut-off value of 3.0 ratio between sample and negative control were considered positive. Single antigen results above an MFI cut-off value of 1000 were considered positive. Before testing, all sera were pretreated with disodium EDTA (final concentration 10 mmol/L, pH 7.4; Sigma-Aldrich, Milan, Italy) (23) , to rule out underestimation of antibody MFI strength due to complement interference that can resemble a prozone effect (23) (24) (25) .
Graft biopsy eluates were tested for class I and class II HLA specific antibodies by SAB analysis using the last washing supernatants of all processed biopsy specimens as internal negative controls. An additional negative control was represented by a mix of the acid plus neutralizing buffer solutions used in the elution procedure (17) . Positivity was assigned to antibodies showing an MFI value higher than 5 SDs of mean negative controls: the MFI cut-off was 90. Assignment of positivity to gDSAs with MFI levels close to the cut-off was also validated by the presence of gDSA single-antigen peaks in the absence of any disturbing background and by the detection of sDSAs having the same HLA specificity of concomitant gDSAs.
Complement binding by sDSAs
Heat-inactivated patient sera were tested with C1qScreen TM (One Lambda) for identification of complement binding antibodies, as described (15) . Antibody positivity was assigned at > 500 MFI.
Serum samples were analyzed for the presence of C3d-binding DSAs with the SAB technology according to the manufacturer's protocol (Immucor Lifecode Transplant Diagnostics, Nijlen, Belgium) (16, 26) .
Attempts to testing C1q-and C3d-binding capabilities on intragraft HLA antibodies were always unsuccessful, likely due to gDSA MFI levels below detection threshold and/or modification/destruction of C1q-binding site on acid elution.
Statistical analysis
Data were described as the mean and SD or median and range if continuous and as count and percent if categorical. To determine differences among patient groups, categorical variables were compared with the use Sixty-five biopsy specimens obtained from 48 patients were evaluated. Seventeen were found to be negative for rejection (group 1); groups 2, 3, and 4 (borderline changes, TCMR, and MI, respectively) included seven biopsy specimens each, while the remaining 27 biopsy specimens (group 5) showed features of AMR (10 acute/ active and 17 chronic, active AMR) ( Table 2 ). The latter group included 24 C4d-positive grade 2 (n = 2) or 3 (n = 22) biopsies and three C4d-negative biopsies from three different patients. All instances of AMR were observed beyond the first posttransplantation year (Table 2) .
Paired serum and graft samples were available and were analyzed for the presence of dnDSAs.
Of the 65 graft biopsies, 28 were found to be positive for gDSAs, with a total of 34 HLA DSA specificities (8 and 26 belonging to class I and class II antigen groups, respectively) ( Figure 1 ). Median MFI values of class I and class II gDSAs were 138 (91-9600) and 260 (92-5900), respectively. In parallel, 81 dn sDSAs (class I, 38; class II, 43) were detected in 39 of the 65 paired sera (Figure 1) ; class II sDSAs had higher median MFI (12 700, range 1163-24 800) than class I sDSAs (4400, range 1000-24 079) (p < 0.005) ( Table 2) . gDSAs were never detected in the absence of sDSAs, whereas in the presence of sDSAs, gDSAs were demonstrated in 72% of biopsy specimens with no differences among histological groups (Table 2) . Table 3 shows, for each biopsy, the locus distribution of the HLA specificities targeted by gDSAs and parallel sDSAs: gDSA specificities always mirrored those recognized by sDSAs. Class II gDSAs were observed in 24 (86%) of the 28 positive biopsy specimens, whereas class I gDSAs were only detected in 6 biopsy specimens (21%) ( Table 3 ). With the exception of two DSAs directed against DR antigens (DR13 and DR53), all other class II gDSAs recognized DQ specificities. Class I antigens recognized by gDSAs included A1, A2, C7, and C18. Paired sera and biopsy samples showed similar rates of class II DSA positivity (92% versus 86%), whereas the percentage of class I sDSA positivity appeared higher than that detected in graft tissue specimens (49% versus 21%; p < 0.05) ( Table 3) .
dn sDSA characteristics associated with graft homing To evaluate sDSA characteristics associated to graft homing, we conducted an analysis based on all dn DSAs found in each serum sample.
Eighty-one dn sDSAs were detected in 39 serum samples obtained at the time of biopsy (Figure 1) . A significantly higher homing capability was expressed by class II compared with class I sDSAs (p < 0.001) ( Table 4) . Graft homing was associated with higher sDSA MFI values, which were significant for class II sDSAs (median MFI: 15 300 for homed class II sDSAs versus 5300 for nonhomed, p < 0.001), while a trend was observed for class I sDSAs (median MFI: 10 256 for homed class I sDSAs versus 3137 for nonhomed; p = 0.053). An ROC analysis showed that an MFI threshold of 10 200 predicted the sDSA homing capability with sensitivity, specificity, and positive and negative predictive values of 79%, 81%, 75%, and 84%, respectively (area under the curve, 0.83) ( Figure 2 ).
As far as complement binding function, both C1q-and C3d-fixing properties of sDSAs resulted in being strongly correlated with antibody homing capability (Table 4 ). In detail, among sDSA specificities, the percentage of C1q binding sDSAs showing intragraft homing was 88% compared with 49% of the nonhomed sDSAs (p < 0.005).
Likewise, a significant difference was observed for C3d-positive sDSAs (47% homed versus 11% nonhomed, p < 0.0005).
To rule out a bias effect due to technical failure in detecting gDSAs, the same analysis was run on the 64 sDSAs detected in the 28 gDSA-positive biopsy specimens, with superimposable results (Table S1 ).
Predictors of dn DSA graft homing Factors associated with dnDSA graft homing were evaluated in a univariate analysis on all patients. No differences in patients' and donors' age or sex and total number of HLA-A, -B, -DR, or -DQ allele mismatches, as well as in maintenance immunosuppression, eGFR at 1 year, and the occurrence of delayed graft function, acute graft rejection, and proteinuria, existed between patients with or without gDSAs. Only HLA-DQA1/-DQB1 mismatches, as sum or DQB1 single locus, and the development of dn sDSAs positively correlated with intragraft deposition of DSAs (Table 1) .
Regarding histological features, evaluated individually and in functional clusters for each patient on the first available biopsy specimen, significant differences between patients with or without DSA graft homing were observed only for antibody-mediated lesions (individual characteristics: ptc, C4d deposition; functional clusters: ptc + g, ptc + g + cg), although a trend was observed for T cell-associated histological damage (i + t, p = 0.07) ( Table 1) .
gDSAs and graft histology In our cohort, gDSAs were detected not only in biopsy specimens exhibiting antibody-mediated histological lesions but also, with similar frequency, in biopsy specimens exclusively characterized by TCMR features, when considering biopsy specimens obtained from sDSApositive patients (Table 2 ). This observation prompted us to analyze the kinetics of DSA intragraft deposition in sequential biopsy specimens from individual sDSApositive patients.
Twenty-three sequential biopsy specimens obtained from 11 patients were available (Table 5) . In four patients, we could detect gDSAs in the initial biopsy specimen, in the absence of antibody-mediated graft lesions (biopsy findings: three TCMR and one borderline change). A progression to AMR was observed in the subsequent biopsy, performed after a median interval of 3.3 (0.9-3.7) years (Table 5) . Interestingly, the same DSA antigenic specificity was consistently observed in sequential biopsy specimens (Table 5) .
We then proceeded to evaluate the Banff histological score distribution in patients with or without gDSAs. Because gDSAs were never detected in the absence of sDSAs, the analysis was carried out in biopsy specimens obtained from sDSA-positive patients. Thirty-nine biopsy specimens obtained from 27 patients (28 gDSA positive and 11 gDSA negative) were analyzed, and no differences were observed in the distribution of antibodymediated lesions (g, ptc, cg, and C4d deposition) as well as interstitial fibrosis and tubular atrophy scores (ci and ct) evaluated individually and in functional clusters (Figure 3 ).
gDSAs and graft outcome Graft outcome was evaluated in the 48 biopsied patients included in the study by comparing gDSA-positive patients (n = 20) with the gDSA-negative group including both sDSA-positive (n = 7) and sDSA-negative (n = 21) patients. All graft losses were due to AMR. A significantly worse outcome was observed in the gDSApositive group (p < 0.05) ( Figure 4A ).
Because gDSAs were detected only in sDSA-positive patients, graft outcome analysis was also performed in this subcohort by comparing gDSA-positive (n = 20) with gDSA-negative patients (n = 7). In this series, characterized by a median follow-up of 34 months (range 6-122) from the first biopsy, no significant difference in graft survival was observed ( Figure 4B ). We then assessed whether the same small cohort of 27 sDSA-positive patients was suitable to reveal a significant impact on graft outcome for other antibody properties, such as MFI and C1q-and C3d-fixing capability of sDSAs. We could demonstrate that patients positive for C3d-binding sDSAs experienced a significantly lower graft survival (p < 0.01) ( Figure S1 ).
Discussion
It is well established that the presence of dnDSAs detected posttransplantation predicts inferior long-term graft survival (6, (11) (12) (13) 15, 16) . Because DSAs are not equivalent in their pathogenicity, researchers are now focusing on risk stratification based on antibody biological properties. Among the latter, DSA graft homing ability has been recently suggested as a severity marker of antibody-mediated injury possibly leading to poor graft outcome (17) .
In this study, we show that (i) the intragraft homing process occurs in a large proportion of biopsies performed in patients with dn sDSAs and is associated with sDSA properties such as MFI and complement-binding ability, in dn sDSA-positive patients; (ii) the presence of gDSAs does not allow stratification for worse antibody-mediated graft lesions and graft loss; and (iii) gDSAs are found not only in overt AMR but also in early phases of antibodymediated graft damage and in the absence of antibodymediated histological lesions.
As suggested in a previous work (17) , when considering our whole cohort, including sDSA-negative patients, the presence of gDSAs was associated with antibodymediated graft lesions and correlated with graft loss. However, when attempting to reach the more desirable goal of identifying, within the sDSA-positive cohort, those patients destined to worse graft outcome, DSA graft homing did not prove useful for risk stratification in either study. In Bachelet et al, it had been argued that this lack of discriminating power could be due to the exiguity of the cohort or the short follow-up. This could also be true for our study, but our population has a median 7-year follow-up and, despite its small size, proved to be appropriate to demonstrate the validity of a different biomarker, such as sDSA C3d-binding ability, as a predictor of graft loss. The absence of any significant differences in graft outcome between gDSA-positive and gDSA-negative patients within the sDSA-positive subcohort seems to suggests that graft homing, although a necessary step to activate the damaging process, may not be sufficient per se to determine a progression to graft loss, unless homed antibodies are endowed, in addition to antigen specificity, with additional characteristics such as Ig class/IgG subclass, complement binding capability, and a strength appropriate to activate the complement cascade up to terminal attack complex (15, 16, (26) (27) (28) (29) (30) (31) .
In our sDSA-positive patients, different from the published evidence (17) , gDSAs were also not associated with severity of histological lesions. This observation likely reflects the peculiarity of our series, largely characterized by biopsy specimens with early lesions obtained from patients with good renal function. In this regard, the availability of sequential biopsy specimens in 23% of the patients allowed us to evaluate the kinetics of gDSA deposition and its relationship with tissue damage. We observed that gDSAs could be detected early, in the absence of antibody-mediated histological lesions, in patients who subsequently progressed to AMR, thus strengthening the concept that antibody homing is the preliminary step of the graft-damaging process (32) . Interestingly, the patients with gDSAs in the absence of AMR had histological findings compatible with borderline changes or TCMR, supporting the evidence that T cell alloresponse may elicit antibody formation (33) , likely through upregulation of HLA epitopes on graft cells, increase in antigen presentation, and stimulation of T cell/B cell cooperation. Because antibody homing is likely a dynamic process, we also observed clearance of gDSAs as well as late detection of gDSAs in patients with AMR. However, as the number of patients with sequential biopsies is scarce, the results have to be taken with caution, also considering that gDSA analysis technique is not yet standardized, and very small fragments of tissue were used.
In our cohort, gDSA positivity was found in 74% of sDSA-positive patients, unlike the 40% sDSA/gDSA concordance reported by Bachelet et al (17) . The reasons for this discrepancy could be manifold. Paucity of the processed kidney tissue material and lack of methodology standardization, as well as clearance of tissue-bound gDSAs by macrophage Fcc receptors and shedding of antibodies from endothelial surface, could be taken into account as possible explanations (17, 34) .
sDSA MFI levels, as well as C1q-and C3d-binding capability, appeared to be important factors regulating homing. Indeed, in our analysis, these antibody properties were significantly higher in homed than in nonhomed sDSAs. The centrality of MFI values in the graft homing process is further supported by our data showing that class II sDSAs were more frequently found in the graft compared with class I, possibly due to their higher MFI. ROC analysis allowed to identify an MFI cut-off value of 10 200, likely representing an indicative parameter of stable antibody homing capability, potentially leading to complement cascade activation. However, sDSAs with lower MFI values can be stably found in the graft, likely depending on a high intrinsic antibody avidity/affinity or high constitutive/cytokine-induced HLA antigen/epitope intragraft expression. The finding that graft homed antibodies represented only about half of all DSAs found in parallel sera leads to some considerations about the immunological hierarchy that dictates humoral alloresponse and determines the pathogenetic process leading to graft damage. In this regard, the skewed repertoire of gDSAs does not reflect the wide pool of antibody specificities, and the comparable numbers of HLA class I and II DSAs, found in the periphery. Indeed, DQ A1/B1 allele mismatch predicts sDSA homing, and DQ-specific antibodies represent the vast majority of sDSAs found in the graft, thus placing DQ locus at the apex of alloresponse hierarchy in nonsensitized kidney recipients (12, 13, 22, (35) (36) (37) . The findings that only a restricted set of sDSAs home in the graft and that the same DSA antigenic specificity is consistently observed in sequential biopsy specimens suggest that the sDSAs found in the graft are the major culprits of graft lesion progression. Consequently, gDSA analysis could be used as a tool to identify precociously the relevant sDSA among the different specificities present in the peripheral blood, whose increase in the following years can indicate the commitment to a lesional phenotype. Monitoring fluctuations of the relevant sDSAs in the peripheral blood may help management of maintenance immunosuppression and provide crucial information on the efficacy of antibody removal and/or downmodulation. Indeed, removal from the periphery of all sDSA specificities but that found in the graft may be an indication of therapeutic failure, which will prompt further intervention.
This study has limitations. On the one hand, the small size did not allow us to perform multivariate analysis to explore the role of the different antibody properties on sDSA homing, and the retrospective design influenced the paucity of sequential biopsies. On the other hand, despite heterogeneity and exiguity of tissue sampling, we could confirm reproducibility of gDSA test and further contribute to the technique standardization process. The demonstration that a stable DSA graft homing represents an early necessary step of HLA antibody damage process enlarges the investigation field to include risk factor analysis at the graft tissue level (38) . Prospective studies on larger cohorts are needed to validate gDSA methodology and its clinical utility and the contribution of graft-related biomarkers to individual immunological risk profiling after kidney transplantation. 
